Showing results (131-140 of 279) with videos related to
Sort By:
Pageof 28
Journal of Comparative Effectiveness Research|November 3, 2020
Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancerSam T Keeping, Shannon Cope, Keith Chan, et al.Clinical Lung Cancer|October 10, 2018
Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With PonatinibTerry L Ng, Hui Yu, Derek E Smith, et al.Acta Oncologica (Stockholm, Sweden)|November 19, 2025
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancerJair Bar, Mona H Cai, Yookyung Christy Choi, et al.Lung Cancer (Amsterdam, Netherlands)|July 28, 2021
Real-world insights into patients with advanced NSCLC and MET alterationsMarisa Bittoni, James Chih-Hsin Yang, Jin-Yuan Shih, et al.European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancerStephen V Liu, D Ross Camidge, Scott N Gettinger, et al.Archives of Pathology & Laboratory Medicine|September 10, 2016
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado ExperienceDara L Aisner, Mathew D Rumery, Daniel T Merrick, et al.Cancer|January 28, 2012
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancerRobert C Doebele, Xian Lu, Christopher Sumey, et al.Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.Neuro-Oncology|July 7, 2016
Updates in the management of brain metastasesNils D Arvold, Eudocia Q Lee, Minesh P Mehta, et al.Pageof 28